Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Initiates Buyback of $10M of Shares

NEW YORK (GenomeWeb News) – Qiagen said in a regulatory document today that it began buying back the euro equivalent of $10 million of its shares on Sept. 10 in the first tranche of a share repurchasing program.

The company will buy back a maximum of 750,000 shares of its common stock on the electronic trading platform of the Frankfurt Stock Exchange during the tranche, which will last until Nov. 1, Qiagen said in a document filed with the US Securities and Exchange Commission. The maximum purchase price on a per share basis will not exceed by more than 10 percent the average closing price for the last five trading days prior to the day of purchase on the exchange.

The company said during its second quarter earnings announcement that it was repurchasing up to $100 million of its shares in a new buyback program.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.